Suppression of T-cell activation by administration of MHC class II-binding peptides.
Adorini
L
L
Sandoz Pharma Ltd., Basel, Switzerland.
Guéry
J C
JC
D000818:Animals; D000949:Histocompatibility Antigens Class II / Q000008:administration & dosage / Q000276:immunology*; D007165:Immunosuppression Therapy; D007167:Immunotherapy; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology*; D051379:Mice; D008815:Mice, Inbred Strains; D010455:Peptides; D013601:T-Lymphocytes / Q000276:immunology*
D000949:Histocompatibility Antigens Class II; D010455:Peptides